project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9LN; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.81; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.47; rna integrity number: 8.5; age at index: 57; days to birth: -21050; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1956; age at diagnosis: 21050; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N1; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 115.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; alcohol history: Not Reported; is ffpe: false; weight: 30.0; composition: Not Reported; days to collection: 76; initial weight: 60.0; sample id: 18cd9543-b21c-41a8-b4d7-a8ba371cca22; sample submitter id: TCGA-ZG-A9LN-01A; portion id: bd6e3e71-0811-4971-b6c3-bac03e0165a8; portion submitter id: TCGA-ZG-A9LN-01A-11; slide id: d49e3571-48c6-476b-9a50-96e113da4968; slide submitter id: TCGA-ZG-A9LN-01A-01-TS1; percent lymphocyte infiltration: 5.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0; section location: TOP;